Status:
COMPLETED
The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients
Lead Sponsor:
Baylor College of Medicine
Conditions:
Hyperglycemia
Diabetes Mellitus
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The investigators hypothesize that includes patient weight and glucocorticoid dose can be used to safely initiate insulin treatment in diabetic/hyperglycemic patients who are to be treated with pharma...
Detailed Description
The target fasting serum glucose (FSG) and pre-meal SG was 90-140 mg/dL, and the random SG was less than 180 mg/dL, taking into consideration the ADA/AACE target glucose levels in non-ICU patients (15...
Eligibility Criteria
Inclusion
- Admission for Chronic Obstructive Pulmonary Disease (COPD) exacerbation.
- Treatment with pharmacological doses of glucocorticoids (GCs) ≥10 mg of prednisone or its equivalent if they are not on maintenance dose of GCs in the outpatient settings.
- Treatment with pharmacological doses of GCs ≥10 mg of prednisone or its equivalent above their maintenance dose of GCs in the outpatient settings.
- Have either a previous diagnosis of diabetes mellitus which has been treated with diet or medications, hemoglobin A1c ≥6.5%, or confirmed inpatient hyperglycemia defined as a fasting laboratory glucose or finger stick reading ≥126 mg/dL or random glucose reading ≥200 mg/dL on two or more determinations.
Exclusion
- Unwilling to sign informed consent.
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT01810952
Start Date
September 1 2010
End Date
September 1 2013
Last Update
February 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St. Luke's Episcopal Hospital
Houston, Texas, United States, 77030